Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

BACKGROUND: Daclizumab is a humanized monoclonal antibody against CD25 that modulates interleukin 2 signaling. The SELECT TRILOGY of clinical studies (SELECT/SELECTION/SELECTED) evaluated the safety and efficacy of daclizumab in patients with relapsing-remitting multiple sclerosis (RRMS). We report...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Neurol
Egile Nagusiak: Gold, Ralf, Radue, Ernst-Wilhelm, Giovannoni, Gavin, Selmaj, Krzysztof, Havrdova, Eva, Stefoski, Dusan, Sprenger, Till, Montalban, Xavier, Cohan, Stanley, Umans, Kimberly, Greenberg, Steven J., Ozen, Gulden, Elkins, Jacob
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2016
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4962457/
https://ncbi.nlm.nih.gov/pubmed/27461166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-016-0635-y
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak